When was Gero founded?

Gero was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Gero located?

Gero is headquartered in Singapore, Singapore. It is registered at Rīga, Silciema iela 22.

Which legal entities is Gero associated with?

Gero is associated with GERO PTE. LTD. and 1 other.

How many employees does Gero have?

As of Sep 30, 2026, the latest employee count at Gero is 145.

Is Gero a funded company?

Gero is a funded company, having raised a total of $25.2M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 2019.

When was the latest funding round of Gero?

Gero's latest funding was a $***** Series A round on Jun 17, 2026, with participation from 1 investor.

What is the annual revenue of Gero?

Annual revenue of Gero is less than $1M as on Dec 31, 2024

Where does Gero rank among its competitors?

Gero ranks 13th amongst 199 active competitors, of which 45 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Gero, which secured $17M in Jun, 2026.

Who are the top competitors of Gero?

Gero's top competitors include Revance Therapeutics, Lineage Cell Therapeutics and Evolus. Among them, Gero secured the most recent funding round in June, 2026.

Gero - 2026 Company Profile, Team, Funding, Competitors & Financials

Gero is a series A company based in Singapore (Singapore), founded in 2018 by Maxim Kholin. It operates as a Developer of physics based artificial intelligence models for drug discovery. Gero has raised $25.2M in funding from Bulba Ventures and Melnichek Investments. The company has 199 active competitors, including 45 funded and 64 that have exited. Its top competitors include companies like Revance Therapeutics, Lineage Cell Therapeutics and Evolus.

Company Details

Developer of physics based artificial intelligence models for drug discovery. These computational tools analyze longitudinal health records to identify causal pathways and biological targets for therapeutic intervention. The technology distinguishes between reversible disease processes and irreversible physiological damage to inform the design of molecules. This approach focuses on mapping human aging trajectories to facilitate the creation of treatments for age related conditions.

Website: www.gero.ai/
Social
Email ID: *****@gero.ai
Registered Address: Rīga, Silciema iela 22

Key Metrics

Founded Year

2018

Location

Singapore, Singapore

Stage

Series A

Total Funding

$25.2M in 4 rounds

Latest Funding Round

Series A, Jun 17, 2026, $*****

Investors

Bulba Ventures & 14 more

Ranked

13^th among 199 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2024

Employee Count

145 as on Sep 30, 2026

Investment & Acquisitions

Pickaboo

Similar Companies

OpenEvidence & 3099 more

View Gero's full profile

Gero is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
GERO CIN: 40002039456 , Latvia, Active	Nov 16, 1995	€0 - €1M (As on Dec 31, 2022)	2 (As on Dec 31, 2022)	-
GERO PTE. LTD. UEN: 201835872R , Singapore, Active	Oct 19, 2018	$0 - $1M (As on Dec 31, 2024)	-

Gero has raised a total funding of $25.2M over 4 rounds. Its first funding round was on May 2019. Its latest funding round was a Series A round on Jun 17, 2026 for $*****. 1 investor participated in its latest round. Gero has 5 institutional investors and 10 angel investors.

Here is the list of recent funding rounds of Gero:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 17, 2026	8658374	Series A	4511831	1085433	3029686	7756421
Oct 18, 2023	7028882	Series A	6192468	2404581	2922172	VitaDAO
Aug 04, 2020	4149584	Series A	3212578	5135949	Bulba Ventures	7679736

Access funding benchmarks and valuations. Sign up today!

View details of Gero's funding rounds and investors

The founders of Gero is Maxim Kholin.

Here are the details of Gero's key team members:

Maxim Kholin: Co-Founder of Gero and founder of 2 other companies, GeroSense and Gero Discovery.
Contact Info: 1 email address and 1 phone number

Gero's Board of Directors

Gero's board has 4 active members. Maxim Kholin and Peter Fedichev are part of team and Yoo Loo Ping and Vladimir Viktorovich Nesteruk are independent board members.

Here is the list of Gero's board of directors:

Name	Type	Representing	Status	Duration
Maxim Kholin	Team	-	Current	7y 11m
Peter Fedichev	Team	-	Current	7y 1m
Yoo Loo Ping	Independent board member	-	Current	4y 0m
ptcoukj	Independent board member	-	Current	2y 2m
roxytff	Independent board member	-	Past	1y 4m
yqnjbml	Independent board member	-	Past	7y 9m
mjwqqtw	Independent board member	-	Past	7y 7m

View details of Gero's Founder profiles and Board Members

Gero's employee count trend

Gero has 145 employees as of Sep 26. Here is Gero's employee count trend over the years:

Uncover Gero's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Gero include Revance Therapeutics, Lineage Cell Therapeutics and Evolus. Here is the list of Top 10 competitors of Gero, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Revance Therapeutics 2002, Newark (United States), Acquired	Developer of neurotoxin aesthetic and therapeutic products for skin treatments	$155M	EW Healthcare Partners, Delphi Ventures & 17 others	70/100
2nd	Lineage Cell Therapeutics 1990, Carlsbad (United States), Public	Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders	$23M	State of California, Juvenescence & 4 others	65/100
3rd	Evolus 2012, Irvine (United States), Public	Developer of aesthetic treatments and procedures	$500K	Daewoong Pharmaceutical, De novo ventures	65/100
4th	Biofrontera 1997, Leverkusen (Germany), Public	Developer of therapies for actinic keratosis using photodynamic therapy	-	Rosalind Advisors, Deutsche Balaton & 1 others	62/100
5th	Galderma 1981, Zug (Switzerland), Public	Manufacturer of products to treat a range of dermatological conditions	-	ADIA, HarbourVest Partners & 2 others	60/100
6th	Hugel 2001, Chuncheon-si (South Korea), Acquired	Developer of therapeutics in the field of aesthetics	-	IMM Investment, SV Investment & 14 others	60/100
7th	Sol-Gel Technologies 1998, United States, Public	Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.	$26M	Westwicke, Arkin Holdings & 6 others	59/100
8th	Collplant 2004, Ness Ziona (Israel), Public	Developer of recombinant human collagen for regenerative medicine and aesthetics	$16.3M	Invesco, Pontifax & 4 others	59/100
9th	SkinMedica 1999, Carlsbad (United States), Acquired	Science-backed skincare delivering transformative results through cleansers, moisturizers, sunscreens, and targeted treatments	$94.2M	http://pseps.com/company/perseus-soros-biopharmaceutical-fund-lp, Aisling Capital ... & 10 others	59/100
10th	Clinuvel 2001, Melbourne (Australia), Public	Biopharma company focused on developing drugs for skin disorders	$51.1M	-	58/100
13th	Gero 2018, Singapore (Singapore), Series A	Developer of physics based artificial intelligence models for drug discovery	$25.2M	Bulba Ventures, Melnichek Investments & 13 others	58/100